Qlife Holding AB announced an extension of its Letter of Intent with Hipro Biotechnology Co., Ltd. regarding a potential reverse takeover transaction, providing additional time for the companies to finalize their strategic merger. The Swedish medical technology company disclosed that the term and exclusivity of the agreement have been extended, with the transaction now conditional upon signing a share purchase agreement no later than December 31, 2025.
Transaction Timeline and Terms
The original transaction was first announced by Qlife through a press release on June 5, 2025. According to the company's latest announcement, all other material terms and conditions of the transaction as previously communicated remain unchanged from the original agreement.
The extension reflects ongoing negotiations between the two biotechnology companies as they work toward completing the reverse takeover structure. Both parties have expressed continued commitment to the strategic rationale underlying the proposed transaction.
Strategic Alignment
"The parties remain fully committed to the strategic rationale of the transaction and are aligned in their intent to execute it as outlined in the Letter of Intent," Qlife stated in its announcement. This alignment suggests that despite the need for additional time, both companies continue to see value in combining their operations through the proposed reverse takeover structure.
Company Background
Qlife is a Swedish company based in Göteborg that develops and markets an innovative medical technology platform called Egoo.Health. The platform aims to provide people with access to clinical biomarker data when testing at home, representing a significant advancement in point-of-care diagnostics and remote patient monitoring capabilities.
The company trades on the Nasdaq First North Growth Market under the ticker symbol QLIFE, with G&W Fondkommission serving as its Certified Adviser. CEO Thomas Warthoe leads the organization as it pursues this strategic transaction with Hipro Biotechnology.
The extended timeline through December 2025 provides both companies with additional months to complete due diligence, finalize terms, and address any regulatory requirements associated with the reverse takeover transaction.
